Trial Profile
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent) and Alemtuzumab (Campath).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Pentostatin (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma
- Focus Therapeutic Use
- 11 Jan 2011 Planned end date changed from 1 Nov 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 11 Jan 2011 Planned end date changed from 1 Nov 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 11 Jan 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.